Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

Core Insights - Absci Corporation and Invetx have formed a strategic partnership to develop a novel Half-Life Extension (HLE) platform for animal health applications using Absci's generative AI drug creation models [1][2][3] Company Overview - Absci is a generative AI drug creation company that integrates AI with scalable wet lab technologies to enhance the development of biologics, aiming to accelerate time to clinic and improve success rates [4] - Invetx specializes in protein-based therapeutics for animal health, focusing on the discovery, development, and manufacturing of veterinary monoclonal antibodies [5] Partnership Details - The collaboration will leverage Absci's expertise in designing Half-Life Extension technologies for human antibodies to address the unmet needs in the animal health market, particularly for companion animals [2][3] - Under the agreement, Absci will create novel modular antibody sequences for specific animal species, while Invetx will have rights to utilize the HLE platform across multiple products [2] - The partnership includes R&D funding, milestone payments, election fees, and royalties on a per-product basis, indicating a structured financial arrangement to support the collaboration [2]